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Distúrbios relacionados ao C9orf72: expandindo o espectro clínico e genético das doenças
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ABSTRACT
Neurodegenerative diseases represent a heterogeneous group of neurological conditions primarily involving dementia, motor neuron
disease and movement disorders. They are mostly related to different pathophysiological processes, notably in family forms in which the
clinical and genetic heterogeneity are lush. In the last decade, much knowledge has been acumulated about the genetics of
neurodegenerative diseases, making it essential in cases of motor neuron disease and frontotemporal dementia the repeat expansions of
C9orf72 gene. This review analyzes the main clinical, radiological and genetic aspects of the phenotypes related to the hexanucleotide
repeat expansions (GGGGCC) of C9orf72 gene. Future studies will aim to further characterize the neuropsychological, imaging and
pathological aspects of the extra-motor features of motor neuron disease, and will help to provide a new classification system that is both
clinically and biologically relevant.
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RESUMO
As doenças neurodegenerativas representam um grupo heterogêneo de condições neurológicas envolvendo fundamentalmente síndromes
demenciais, doenças do neurônio motor e distúrbios de movimento. Relacionam-se, em sua maioria, a processos fisiopatológicos
distintos, destacadamente nas formas familiares em que a heterogeneidade clínica e genética são exuberantes. Na última década, muito
conhecimento se acumulou a respeito da genética das doenças neurodegenerativas, tornando-se bastante importante nos casos de
doenças do neurônio motor e de demência frontotemporal as expansões de repetições do gene C9orf72. Esta revisão aborda os principais
aspectos clínicos, radiológicos e genéticos relativos aos fenótipos relacionados à expansão de repetição do hexanucleotídeo (GGGGCC) no
gene C9orf72. Estudos futuros vão objetivar a caracterização dos aspectos neuropsicológicos, de imagem e patológicos dos achados
extra-motores da doença do neurônio motor e ajudarão a fornecer um novo sistema de classificação relevante em termos clínicos e
biológicos.
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Neurodegenerative diseases represent a heterogeneous
group of neurological conditions primarily involving dementia,
motor neuron disease and movement disorders. A wide group
of different pathophysiological and genetic mechanisms are
involved in this group. Knowledge regarding the genetic basis
of sporadic and familial cases of neurodegenerative disorders is
growing and new evidences about the involvement of pre-
viously unknown genes are the rule. This is particularly true
in cases with complex motor and cognitive phenotypes.
Motor neuron disease comprises four main different clin-
ical forms of upper and lower motor neuron involvement:
primary lateral sclerosis; progressive muscular atrophy; pro-
gressive bulbar palsy; and amyotrophic lateral sclerosis
(ALS). ALS represents the most common form of progressive
neurodegenerative motor neuron disease with upper and
lower motoneuron compromise, clinically defined through
specific clinical and electroneuromyographic diagnostic cri-
teria, the so-called El Escorial revised criteria and the
Awaji-shima electrodiagnostic criteria. However, ALS is more
than a pure motor neuron disease. It is a heterogeneous syn-
drome with clinical, pathological and genetic overlap with
frontotemporal dementia1.
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Frontotemporal lobar degeneration (or simply frontotem-
poral dementia) (FTD) represents one of the most common
and wide studied neurodegenerative group of cognitive and
behavioural conditions, generally giving rise to an early-
onset dementia with behavioural disturbances involving
three particular clinical syndromes2,3,4: the so-called beha-
vioural variant frontotemporal dementia (bvFTD), semantic
variant of primary progressive aphasia (svPPA) and nonflu-
ent/agrammatic variant of primary progressive aphasia
(nflvPPA). A logopenic variant of primary progressive apha-
sia has also been considered.
Despite its major presentation as a cognitive and beha-
vioral disturbance, in some cases of FTD, motor involvement
is prominent. Since 2006, there is growing evidence about the
participation of a major gene locus involved in FTD and ALS
phenotypes located on chromosome 9p (the previously
known chromosome 9p-linked FTD with ALS)4,5, which subse-
quently in 2011 proved to represent an hexanucleotide repeat
expansion in the non-coding region of C9orf72 gene6,7.
ALS can be viewed as resulting from a complex conver-
gence of genetic susceptibility, age-related loss of cellular
homeostasis, and possible environment influences. The rapid
increase in recent years of the number of genes in which
mutations have been associated with ALS has led to in vitro
and in vivo models that have generated a wealth of data indic-
ating disruption of specific biochemical pathways and sub-
cellular compartments, including protein misfolding, mRNA
splicing, axonal transport, oxidative stress, proteasome and
mitochondrial dysfunctions (Figure 1). Since the identification
of the C9orf72 gene, the mechanisms of the interaction
between cellular degeneration and system level degeneration
have been better elucidated, providing a roadmap for devel-
oping novel treatments based on specific targeting of gene
mutations. The aim of this review is to focus in the main
information regarding genetic, pathophysiological, clinical
and neuroimaging features of C9orf72-related disorders.
EPIDEMIOLOGICAL PROFILE
The overall prevalence of ALS ranges from 2-7 cases per
100,000 inhabitants1. A minor proportion of 5% of ALS cases
represent familial autosomal dominant ALS cases8. In the last
decade, SOD1 mutations were considered the most common
genetic form of familial ALS1. However, great knowledge was
obtained from new gene discovery allowing a more compre-
hensive approach in the previously unidentified familial cases.
Mutations in the C9orf72 gene represent up to 50%-60% of
cases of familial ALS and up 10% of sporadic ALS in some
locations, but with an average of one third of familial cases9,10.
It is also believed that most sporadic cases of ALS under the
general assignment of unknown or unidentified genetic cause
may be originated by C9orf72 mutations11,12.
FTD presents with a global average prevalence of 15-22
cases per 100,000 inhabitants. Around 40%-50% of FTD cases
present with a positive family history of dementia, mainly with
autosomal dominant inheritance pattern13. It is estimated that
up to 18%-24% cases of familial FTD and 6%-10% of sporadic
cases of bvFTD are due to C9orf72 expansions5,14,15.
C9orf72 repeat expansions have a wide global distri-
bution, mainly in European-derived populations, and an
exceptionally low prevalence in East Asian populations
and probably in South and Southern Asia regions16. In cases
of FTD in Europe (including patients from 15 countries),
C9orf72 repeat expansions were detected with high fre-
quency in Finland (29.3% of all cases), in Spain (25.5%)
and in Sweden (20.7%), and low prevalence was detected
in Germany (4.8%). In a large group of patients from USA,
Europe and Australia, the overall C9orf72 prevalence was
7% of sporadic ALS, 39.3% of familial ALS, 6% of sporadic
FTD and 24.8% of familial FTD3. Other series form London
patients with the FTD-ALS phenotype, 26% presented with
the C9orf72 expansion followed by 24% in SOD1 gene, 4%
in FUS gene and 1% in TARDPB gene17, showing that
C9orf72 represents the most common genetic cause of famil-
ial cases of FTD-ALS in Europe18.
GENETIC ASPECTS AND PATHOPHYSIOLOGY
Familial and sporadic cases of ALS and FTD have been
linked to several genomic regions, most related to one or
Figure 1. Schematic representation of the main pathophysio-
logical mechanisms involved with motor neuron disease, (1)
including protein misfolding, (2) altered RNA processing
(mainly disturbed mRNA splicing), (3) defects in axonal
transport, (4) abnormal accumulation of reactive oxygen
species, (5) mitochondrial dysfunctions, (6) microglial neu-
roinflammatory mechanisms, (7) direct excitotoxicity by astro-
cytes, (8) disturbances of autophagy, (9) proteosome
abnormalities and (10) ion channel defects.
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more different mechanisms of neurodegeneration11,19,20. An
extensive number of genes located in different chromosome
regions and related to distinct patophysiological mechan-
isms have been linked to clinical and neuropathological find-
ings of FTD and ALS (Tables 1 and 2)4,11,14,20,21.
C9orf72 (chromosome 9 open reading frame 72) gene (MIM
*614260) represents a reasonably recently described gene
linked to sporadic and familial cases of neurodegenerative
disorders. Heterozygous hexanucleotide repeat expansions
in a noncoding region of the gene are responsible for its
pathogenesis, in a similar pattern of other repeat expansion
disorders22,23,24 (Table 3). C9orf72-related disorders represent
clinical and pathologically heterogeneous autosomal dom-
inant neurodegenerative diseases with partial (or incomplete)
penetrance, giving rise to pleiotropic manifestations. The
pathogenic repeat expansion is fully penetrant around 80
Table 1. Genetic causes of frontotemporal dementia4,20,21.
Gene involved (locus) Pattern of inheritance
C9orf72 (Chromosome 9 Open Reading Frame 72; 9p21.2) Autosomal dominant
GRN (Progranulin; 17q21.31) Autosomal dominant (3%-26% of all cases)
VCP (Valosin-containing Protein; 9p13.3) Autosomal dominant
TARDBP (TAR DNA-binding protein; 1p36.22) Autosomal dominant
MAPT (Microtubule-associated Protein Tau; 17q21.31) Autosomal dominant (40%-50% of all cases)
CHMP2B (Chromatin-modifying protein member 2B; 3p11.2) Autosomal dominant
PSEN1 (Presenilin 1; 14q24.2) Autosomal dominant
UBQLN2 (Ubiquilin 2; Xp11.21) X-linked
CHCHD10 (Coiled-coil-helix-coiled-coil-helix-domain-containing protein 10; 22q11.23) Autosomal dominant
Table 2. Genetic causes of amyotrophic lateral sclerosis (familial and sporadic cases)11,14,20.
Gene involved (locus) Pattern of inheritance
SOD1 (Superoxide dismutase 1; 21q22.11)
Autosomal dominant or recessive (12%-13% of familial; 2%
of sporadic)
C9orf72 (Chromosome 9 Open Reading Frame 72; 9p21.2) Autosomal dominant
FUS (Fused in Sarcoma; 16p11.2)
Autosomal dominant or recessive (5% of familial; , 1% of
sporadic)
CHMP2B (Chromatin-modifying protein member 2B; 3p11.2) Autosomal dominant
ALS2 (Alsin; 2q33.1) Autosomal recessive
UBQLN2 (Ubiquilin 2; Xp11.21) X-linked
PFN1 (Profilin 1; 17p13.2) Autosomal dominant
OPTN (Optineurin; 10p13) Autosomal recessive or dominant
TARDBP (TAR DNA-binding protein; 1p36.22) Autosomal dominant (5% of familial)
SQSTM1 (Sequestosome 1; 5q35.3) Autosomal dominant
PRPH (Peripherin; 12q13.12) Sporadic
HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1; 12q13.13) Autosomal dominant
DCTN1 (Dynactin 1; 2p13.1) Autosomal dominant
ANG (Angiogenin; 14q11.2) Autosomal dominant
FIG4 (FIG4, S. cerevisiae, homolog of SAC1 lipid phosphatase domain
containing; 6q21)
Autosomal dominant
NEFH (Neurofilament protein, Heavy Polypeptide; 22q12.2) Autosomal dominant
VCP (Valosin-containing Protein; 9p13.3) Autosomal dominant
SETX (Senataxin; 9q34.13) Autosomal dominant
ERRB4 (V-Erb-B2 avian erythroblastic leucemia viral oncogene homolog 4;
2q34)
Autosomal dominant
SIGMAR1 (Sigma Nonopioid Intracellular Receptor 1; 9p13.3) Autosomal recessive
VAPB (Vesicle-associated Membrane Protein-associated Protein B;
20q13.32)
Autosomal dominant
MATR3 (Matrin-3; 5q31.2) Autosomal dominant
CHCHD10 (Coiled-coil-helix-coiled-coil-helix-domain-containing protein 10;
22q11.23)
Autosomal dominant
DAO (D-amino acid oxidase; 12q24) Autosomal dominant
ATXN2 (ataxin 2; 12q24.12) Autosomal dominant
SMN1 (Survival of Motor Neuron 1; 5q13.2) Autosomal dominant
EWSR1 (Ewing sarcoma breakpoint region 1; 22q12.2) Autosomal dominant
TAF15 (TAF15 RNA polymerase II, TATA box-binding protein-associated
factor, 68-kD; 17q12)
Autosomal dominant
SPG11 (SPG11 gene/spatacsin; 15q21.1) Autosomal recessive
TUBA4A (Tubulin, alpha-4A; 2q35) Autosomal dominant
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years, but no penetrance is found in individuals younger than
35 years3. In some cases, anticipation has been observed, but
less prominent than in other expansion repeat expansion dis-
eases. An european founder effect has been detected for the
expansion in Scandinavia, more specifically in Finland16.
The C9orf72 gene is located on 9p21.2 and is formed by
12 exons, coding 3 transcription variants and two protein
isoforms (a, b). Transcript variants 1, which contains non-
conding exons 1b, and 3, which contains noncoding exon
1a, are fused to coding exons 2 through 5 and encode a
longer isoform of the protein with 481 amino acid (called iso-
form a). Transcript variant 2, which contains exon 1a,
encodes a shorter protein with 222 amino acid (called iso-
form b), highly expressed in testis, fetal brain, cerebellum
and frontal cortex16.
The expansion site is located in the 5’ regulatory region
upstream of the transcription start site between two non-
coding exons (1a, 1b) in the core promoter for transcript
variant 1, leading to haploinsufficiency mechanism with
variable degrees of reduction of isoform a. For transcription
variants 2 and 3, the expansion is located in intron 1, leading
to aberrant and abnormal production with classical gain-of-
function mechanisms participating in toxic pathogenetic
mechanisms and influencing the processing of precursor
mRNAs (Figure 2). Hexanucleotide repeat expansion also
forms DNA and RNA G-quadruplexes which promotes the
formation of RNA/DNA hybrids (R-loops), originating a
repeat length-dependent accumulation of transcripts which
bind to ribonucleoproteins, such as nucleolin, giving rise to
nucleolar stress16,25.
Loss-of-function by means of happloinsufficiency repre-
sents the main mechanism involved in its pathogenesis
(Figure 3). The C9orf72 encoded protein is found in presy-
naptic terminals and cytoplasmic regions of neurons in a dif-
fuse pattern and is still poorly understood. One of the main
hypotheses regarding its function propose a similar function
to guanine nucleotide exchange factors for small GTPases
associated with the regulation of Rab protein system during
endosomal trafficking regulation of exocytosis and endocyto-
sis (with the Rab protein system) in neuronal cell lines, prim-
ary cortical neurons and spinal cord motor neurons. It gives
rise to a higher rate of lysosomal protein degradation and
abnormal accumulation of ubiquinated proteins26. The
C9orf72 encoded protein also participates in mechanisms
of neuronal autophagic process and interacts with nuclear
proteins involved with regulation of splicing and RNA meta-
bolism18.
C9orf72 expansion-mediated toxicity occurs by accu-
mulation of toxic RNA foci and RNA-binding proteins with
secondary dysregulation of RNA splicing and trafficking,
and inappropriate formation of novel dipeptide aggregates
resulting from non-ATG mediated (RAN) translation of the
hexanucleotide repeat (colocalized with p62+ inclusions)27.
Most cases result from gain-of-function mechanisms directly
related or not to the encoded protein. RNA-mediated cyto-
toxic nuclear and cytoplasmic mechanisms may occur first
Table 3. Clinical neurological diseases associated with the genetic mechanism of unstable nucleotide repeat expansion22,23,24.
Class of nucleotide repeat
expansion
Neurological disorder (gene involved; locus)
Nucleotide repeat sequence (pathological
number of repeats)
Trinucleotide
Fragile X syndrome (FRAXA) (FMR1; Xq27.3) CGG (. 200)
Fragile X tremor/ataxia syndrome (FXTAS) (FMR1; Xq27.3) CGG (55-200)
X-linked mental retardation associated with fragile site
(FRAXE) (FMR2/AFF2; Xq28)
CCG (. 200)
Huntington’s disease (HTT; 4p16.3) CAG (. 37)
Huntington disease-like 2 (JPH3; 16q24.2) CAG (. 41)
Friedreich’s ataxia (FXN; 9q21.11) GAA (70 - . 1000)
Spinocerebellar ataxia type 1 (ATXN1; 6p22.3) CAG (40-83)
Spinocerebellar ataxia type 2 (ATXN2; 12q24.12) CAG (32-79)
Spinocerebellar ataxia type 3 (ATXN3; 14q32.12) CAG (52-86)
Spinocerebellar ataxia type 6 (CACNA1A; 19p13.2) CAG (19-33)
Spinocerebellar ataxia type 7 (ATXN7; 3p14.1) CAG (36-306)
Spinocerebellar ataxia type 8 (ATXN8 and ATXN8OS; 13q21) CTG*CAG (71-1300)
Spinocerebellar ataxia type 12 (PPP2R2B; 5q32) CAG (51-78)
Spinocerebellar ataxia type 17 (TBP; 6q27) CAG/CAA (47-63)
Dentatorubral-pallidoluysian atrophy (ATN1; 12p13.31) CAG (49-93)
Kennedy disease (AR; Xq12) CAG (38-62)
Myotonic dystrophy type 1 (DMPK; 19q13.32) CTG (. 50)
Oculopharyngeal muscular dystrophy (PABPN1; 14q11.2) GCG (12-17)
Tetranucleotide Myotonic dystrophy type 2 (ZNF9; 3q21.3) CCTG (75-11.000)
Pentanucleotide Spinocerebellar ataxia type 10 (ATXN10; 22q13.31) ATTCT (400-4500)
Hexanucleotide
Spinocerebellar ataxia type 36 (NOP56; 20p13) GGCCTG (650-2500)
FTD ± ALS (C9orf72; 9p21.2) GGGGCC (250-1600)
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in astrocytes and result from RNA foci formation, not found
in sporadic ALS or familial FTD-ALS causes by other gene
mutations28,29. Aggregate formation occur mainly through
proteasome dysfunction, commonly found in C9orf72-related
ALS and FTD cases. Genetic instability, dysfunction of the
promoter region, abnormal mRNA distribution, splicing
Figure 2. Schematic representation of C9orf72 gene structure and its transcript variants produced by alternative splicing.
Figure 3. Pathophysiological mechanisms involved with abnormal RNA processing in C9orf72-related disorders. The aborted RNA
transcript can migrate to cytoplasm and give rise rybosomal traduction of abnormal misfolded protein with unknown functions
and originate aggregates of C9-related abnormal proteins, frequently seen in immunohistochemical analysis as intraneuronal
intracytoplasmic inclusions. The aborted RNA transcript can also participate in complex intranuclear interactions and promote
nucleolar stress. Both mechanisms participate as particular pathophysiological mechanisms seen in C9orf72-related FTD-ALS.
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and translation are also linked to the formation of G-quad-
ruplexes (or G-tetrads) of uni and multimolecular RNA24.
Besides this intraneuronal mechanisms, it has been demon-
strated that ALS patients carrying C9orf72 mutations have
astrocytes that convey toxicity towards motor neurons30.
The so-called GGGGCC (G4C2)n hexanucleotide repeat
expansion, in the normal asymptomatic individual, ranges
from 2 to 19 repeats, despite the fact of up to 30 repeats
being also considered normal. However, asymptomatic
patients have also been described in cases with the repeats
in the pathogenic interval. Symptomatic patients are
described in cases with more than 30 repeats, generally with
250 to 1,600 repeats, and more symptomatic in cases with
more than 400 repeats16,19.
NEUROPATHOLOGICAL ASPECTS
Neuropathological studies have been widely performed
in C9orf72-related disorders. Gross pathology examination
generally shows global brain atrophy, particularly of the
frontal and temporal lobes with mild to moderate subcorti-
cal involvement. Microscopic evaluation unveils neuronal
degeneration and loss with variable degrees of gliosis and
superficial laminar spongiosis (depending on disease stage),
but rarely with Pick bodies and with relative paucity of amy-
loid plaques and neurofibrillary tangles. Myelin loss in the
corticospinal tracts with moderate to severe degeneration
of the motor system is also described in cases of FTD even
without clinical features of motor neuron disease9,19. Marked
loss of lower motor neurons in cranial nerve motor nuclei in
the brainstem (mainly in the medulla) and in the anterior
horns of the spinal cord with marked microglial reaction is
observed in all levels of the pyramidal tract in cases with
associated ALS phenotype19.
Immunohistochemistry patterns represent important
findings in C9orf72 neuropathological studies. The finding
of TDP-43 (TAR/transactive response DNA-binding protein
43) positive cytoplasmic inclusions in spinal motor neurons
and eventually in glial cells, commonly associated with cyto-
plasmic neuronal ubiquitin-positive and Tau-negative inclu-
sions in the cortex and spinal cord19,31,32. The absence of FUS
and Ubiquilin 2 positive inclusions differentiate C9orf72
spectrum from other genetic forms of FTD-ALS disorders14.
Another highly specific, nearly pathognomonic, molecu-
lar signature of C9orf72-related neuropathology is the finding
of TDP-43 negative and p62-positive neuronal cytoplasmic
inclusions in extra-motor regions within the dentate gyrus
granule cells, in the CA4 pyramidal cells of the hyppocam-
pus, in the frontal neocortex and in granule cells of the cere-
bellum19,33. These represent dipeptide repeat proteins,
previously described, formed as a result of sense and anti-
sense repeat associated non ATG-initiated translation of
the expanded repeat noncoding region9,27. Dopaminergic
neuron loss in substantia nigra is also common in C9orf72
cases of ALS with p62-positive inclusions and without a-
synuclein-positive Lewy bodies thus in a distinct pattern of
involvement than in idiopathic Parkinson disease34.
Although classically described in motor neurons in
anterior horn of the spinal cord in ALS cases and rarely in
association with atypical Pick’s disease, eosinophilic intra-
neuronal inclusions rich in transferrin and cystatin C, the
so-called Bunina bodies, have also been reported in cases
of FTD-ALS in C9orf72-related repeat expansion, despite
not representing a significant finding in this context35.
CLINICAL AND LABORATORY CHARACTERIZATION
The association of ALS and FTD with other neurological
phenotypes is widely known from the past36, including the
first descriptions of FTD-ALS complex about 40 years ago.
C9orf72 repeat expansions are involved with a wide spectrum
of neurological manifestations37,38, involving motor and non-
motor (cognitive and behavioral) phenotypes (syndromes)38
(Figure 4). Most clinical data come from populational studies
in European countries and in US. It is possible to extend con-
cepts obtained from the analysis of such populations to
propose a proper overall analysis. Hexanucleotide repeat
expansions in C9orf72 gene have been described in different
contexts of neurodegenerative syndromes, ranging from
classical bvFTD to sporadic Creutzfeldt-Jakob disease-like
phenotype39. Few data regarding Brazilian patients with
C9orf72-related disorders exist, but in general presenting with
classical behavioural and extrapyramidal (focal dystonia,
parkinsonism) compromise findings40.
Since 2011, C9orf72 gene has become a leading figure in
the genetics of neurodegenerative processes involving motor
neuron disease and dementia. There is frequent misunder-
stood regarding the FTD-ALS complex and the lytico-bodig
disease or amyotrophic lateral sclerosis-parkinsonism-
dementia complex, previously described in the Chamorro
population from Guam Island in USA. The clinical picture
arises from mutations in the TRPM7 gene (Transient receptor
potential cation channel, subfamily M, member 7; 15q21.2), as
a consequence from direct exposure to the neurotoxic
effects of b-methylamino-L-alanine found in local Guam
species of flying fox (Pteropus tokudae)41.
The most common clinical presentation related to
C9orf72 is represented by adult-onset of bvFTD phenotype
followed in the disease course by variable signs of a motor
neuron disease, resembling ALS5. Semantic dementia and
progressive non-fluent aphasia have rarely been described
in association with motor neuron signs9, but might not
exclude the hypothesis of C9orf72 gene hexanucleotide
repeat expansion13. Neuropsychiatric profile involves early
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disinhibition (up to 85%), lack of insight (up to 78%), hallu-
cinations (up to 50%), delusion (up to 50%), anxiety (up to
52%), hyperorality (up to 100%), early apathy (up to 100%),
loss of empathy (up to 77%) and obsessive-compulsive symp-
toms (up to 12%)5,42,43. There is an important clinical overlap
with probable Alzheimer’s disease in the early-onset cases,
mainly in Caucasian patients45,46, making it difficult to pro-
mote a proper genetic evaluation in association with clas-
sical genes (APP, PSEN1, PSEN2)47,48, although such cases
generally present with an older age than with the FTD clin-
ical spectrum26. UBQLN2 gene mutations are great mimick-
ers frequently differentiated in clinical means by the
absence of psychiatric features (not behavioural symptoms)
and lower motor neuron involvement14. In cases with pleio-
tropic heterogeneous phenotypic variability of repeat expan-
sions, association with previously described pathogenic
mutations in GRN or MAPT genes must be done49.
During the natural history of ALS, up to 50% of patients
have cognitive decline, but only 15%-20% full-fill clinical cri-
teria for FTD10,14. In C9orf72 related ALS, despite the preval-
ence of 35% with at least one family member with
dementia19 and the higher rate of cognitive dysfunction,
the most significant manifestations include psychiatric
symptoms (delusions and hallucinations) and higher rates
of familial members with parkinsonism8.
There are no specific clinical hallmarks which differenti-
ate FTD and ALS phenotypes linked to C9orf72 to those
associated with other genes. C9orf72-spectrum disorders
tend to have a lower age of onset, shorter survival, more
rapid clinical course, bulbar symptoms at onset (in cases
of ALS phenotype), propensity toward psychosis, early-onset
delusions (up to 45%), paranoia or late-onset hallucinations
(up to 50%). Early-onset delusion in the context of ALS is
highly suggestive of C9orf72 expansions5, despite the absence
of a specific neuropsychiatric symptom pattern2. There is
also an increased incidence of neurodegenerative disease
in relatives (mainly dementia in 33% of cases) when com-
pared to patients with other forms of ALS or FTD, even in
the rare cases without clear cognitive dysfunction5,9,10,19.
Parkinsonism is a key feature in C9orf72-spectrum pheno-
type. Early-onset mild parkinsonism (mainly akinetic-rigid)
with focal dystonia and poor response to levodopa is the typ-
ical clinical picture, rarely presenting with diffuse Lewy body
dementia parkinsonism. It is also documented the predisposi-
tion of some populations to parkinsonism in cases of C9orf72
repeat expansion12. Atypical parkinsonism with cerebellar
ataxia mimicking multiple system atrophy has also been
described49, the same way as cerebellar ataxia with retained
reflexes50 and isolated olivopontocerebellar atrophy with
hot-cross bun sign in the pons26,51. Due to its exceptionality,
cerebellar ataxia as a clinical manifestations of C9orf72 expan-
sion should be suspected only in cases with proper familial
dementia or especially with motor neuron disease. There
are no specific repeat intervals involved with atypical parkin-
sonism and cerebellar ataxia26.
Another phenotype on growing evidence and importance
is represented by Huntington’s disease (HD) phenocopies,
cases in which typical or suspected cases of HD present with
negative genetic testing52 (Table 4). Most cases studied pre-
sented with earlier age at onset and a different combination
of movement disorders, including dystonia, tremor, rigidity,
myoclonus and chorea, thus with a broader spectrum than
HD classical phenotype. One highly suggestive clinical con-
text is the presence of upper motor neuron features in cases
of HD-like phenotype. ALS-like phenotype mainly with lower
motor neuron signs in this context is rarely associated
with the HD, FTD and C9orf72 clinical spectrum. There is
no specific size of repeat expansion linked to this phenotype,
making part of the set of most expansion sizes in other clin-
ical situations linked to C9orf7253.
Figure 4. Summary of motor and non-motor (cognitive and behavioral) syndromes associated with C9orf72 gene hexanucleotide
repeat expansion. FTD: Frontotemporal dementia; ALS: Amyotrophic lateral sclerosis; HD: Huntington disease; CJD:
Creutzfeldt-Jakob disease.
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During a large screening for genetic causes of early-onset
autosomal dominant inherited dementia, atypical clinical
presentations of C9orf72-related disease were found and dis-
closed a rare presentation of an olivopontocerebellar degen-
eration and a corticobasal syndrome-like phenotype51.
Visuospatial dysfunction has also been described, but the
phenotype of pure spastic paraparesis is not associated with
repeat expansion38. It has also been identified a higher pre-
valence of multiple sclerosis within families with ALS, mainly
those associated with C9orf7219.
It has also been described an uncommon psychiatric
phenotype with familial bipolar disorder with C9orf72 expan-
sion with one family member with late-onset features which
progressed to frontotemporal lobe degeneration54. Repeat
expansions were rarely described in cases of men with
refractory depression that harboured a previous suspected
diagnosis of depressive pseudodementia55. Some authors
even suggest the possibility of performing C9orf72 gene
evaluation in cases of late-onset psychosis56. Suicide attempt
is also a clinical presentation linked to the repeat expansion.
Those carrying the C9orf72 repeat expansion are also more
likely to have family members with neuropsychiatric condi-
tions, including psychosis and a history of suicide57.
General serum laboratory profile is completely normal.
Expansions can be properly detected with repeat-primed
PCR and Southern blotting approaches. Large series of elec-
troneuromyographic pattern evaluations and muscle biopsies
in C9orf72 have not been studied, but do not differ from spora-
dic cases of ALS without this same genetic profile. No specific
CSF examination findings and biomarkers are available and
most range usually in normal levels (beta amyloid, tau, phos-
phorylated tau, tau-to-beta amyloid ratio), although some
patients present with an Alzheimer’s disease-like CSF profile16.
NEUROIMAGING STUDIES
There is a wide radiological and pathological correlation
in cases of C9orf72. However, no pathognomonic findings on
cranial CT and brain MRI have been described2. Most neuroi-
maging descriptions were performed in cases linked to any
degree of cognitive of compromise or behavioral distur-
bances. Symmetrical frontal and temporal lobe, insular,
and posterior cortical (parietal and occipital) atrophy are
the rule mainly when associated with subcortical involve-
ment of the thalamus and cerebellum, rarely described in
other genetic forms of FTD and which tend to progress
and accent during disease course (Figure 5). The degree of
temporal involvement may be less prominent than that seen
in other genetic causes of FTD, despite severe clinical
involvement. One notorious exception with predominant
temporal atrophy is represented by C9orf72-related cases
with primary progressive aphasia phenotype58. The finding
of hot-cross bun sign in the pons has also been described
in the context of C9orf72-spectrum in a single case of
late-onset cerebellar variant of multiple system atrophy-
like phenotype49.
In cases of C9orf72-related ALS, volumetry and morpho-
metry brain MRI studies also disclosed prominent atrophy of
right inferior and superior frontal gyri, right precentral gyri
and left anterior cingulate cortex10. The same group of
changes linked to the FTD phenotype are also present in
the ALS phenotype9, although the presence of bilateral tha-
lamic atrophy is rarely described in cases of isolated ALS
phenotype59. The presence of the “bright tongue sign” in
the context of a frontotemporal dementia points to the pos-
sibility of associated motor neuron disease60.
No specific or highly-suggestive patterns have been
described in positron emission tomography (PET) and
single-photon emission computed tomography (SPECT).
However, some pathological changes have been pointed
out. SPECT shows hypoperfusion in the anterior and
middle cingulate gyri, and variable degrees of frontal cor-
tical hypometabolism in PET, although these findings
do not represent a rule and depend on disease stage
of evolution58.
It is also possible to differentiate general neuroimaging
patterns in the FTD spectrum with impaired C9orf72
with other high prevalence genes as GRN and MAPT.
Exceptionally mutations in these genes originate thalamic
and cerebellar atrophy, which represents important differ-
ential diagnostic findings. GRN gene mutations are commonly
Table 4. Differential diagnoses of genetic causes of Huntington’s disease-like syndromes52.
Groups of neurological conditions linked to Huntington’s disease phenocopies
I
Classical Huntington
disease-like
Huntington disease-like types 1, 2, 3
II Degenerative ataxias
Ataxia-telangiectasia, Ataxia-telangiectasia-like disorder; Ataxia with oculomotor
apraxia types 1, 2, 3; Friedreich ataxia; Dentatorubral-Pallidoluysian atrophy;
Spinocerebellar ataxias types 1, 2, 7, 8, 14, 17
III Neurometabolic disorder Aceruloplasminemia, Wilson disease, Lesch-Nyhan syndrome
IV Miscellanea
C9orf72-related disoders, Neuroferritinopathy (Neurodegeneration with Brain
Iron Accumulation type 3), Pantothenate Kinase-Associated Neurodegeneration
(Neurodegeneration with Brain Iron Accumulation type 1), Neuroacanthocytosis
type McLeod, Choreoacanthocytosis, Kufor-Rakeb syndrome
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associated with asymmetric hemispheric atrophy, predomi-
nantly in the inferior frontal, superior temporal and inferior
parietal gyri, eventually associated with any degree of leu-
koencephalopathy. MAPT gene mutations are associated with
symmetric frontotemporal atrophy, predominantly in the
anterior and medial portions of the temporal lobes, the fornix
and orbitofrontal cortex, possibly with cerebellar involve-
ment10,58.
THERAPEUTIC PERSPECTIVES
Symptomatic therapy remains the exclusive drug meas-
ure in cases of FTD and ALS besides the proper use of multi-
disciplinary approaches. Developing new therapy modalities
provide new multimodal treatment perspectives for most
inherited and sporadic cases of FTD-ALS patients. Most data
regarding C9orf72-targeted therapies derive from other
repeat expansion neurodegenerative disorders. New dis-
ease-modifying therapies are being studied as new attempts
on ALS and FTD therapeutics rather than neuroprotective
approaches. However, few specific clinical trials, none exclu-
sively with C9orf72 mutations.
Dexpramipexole, Riluzole and Fingolimod represent
neuroprotective perspectives in cases of FTD-ALS13.
Patient-specific induced pluripotent stem cell therapy,
immunotherapies, antioxidant agents, minocycline, insulin-
like growth factor-1 (IGF-1) and lithium carbonate are other
alternative treatment options used in preclinical studies13,14.
Most recent attempts target mRNA dysfunctions in FTD-
ALS, mainly the aberrant splicing process, the nuclear
RNA-binding proteins and contentes from nuclear inclu-
sions. The use of antisense oligonucleotides to silence
targeted mRNA or to modulate splicing represents an
important perspective in the therapy of C9orf72-related dis-
orders, applying clinical research data obtained from mus-
cular dystrophies, spinocerebellar ataxias and chronic
lymphocytic leukemia14,29.
CONCLUSION
The spectrum of neurological conditions associated
with hexanucleotide repeat expansion of C9orf72 gene is
very broad, ranging from the classic phenotype of motor
neuron disease and frontotemporal dementia to the
most recently descriptions of parkinsonian syndromes,
Huntington’s disease-like phenocopies, Alzheimer’s dis-
ease-like phenotypes and rarely cerebellar ataxias and
other psychiatric disorders. Extensive studies of neuroima-
ging, molecular neurogenetics and neuropathology allowed
the knowledge of specific information related to C9orf72
phenotypes. Clinicians must be aware about such clinical
and neuroimaging spectrum related to C9orf72 for proper
investigation of suspected cases in the setting of neurode-
generative disorders.
Figure 5. Neuroimaging features described during early (A) and advanced (B) stages of C9orf72-related spectrum disorders. (A)
Axial FLAIR-weighted brain MRI disclosing early stage changes represented by mild frontal and temporal lobe atrophy; and (B)
Axial T2-weighted brain MRI disclosing a typical end-stage pattern represented by marked symmetrical frontal and temporal
atrophy with cerebellar and thalamic atrophy.
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